MedWatch

Coloplast prepares big study of main asset from million-dollar acquisition

After the acquisition of Nine Continents Medical, Coloplast is getting ready to try out the US-based urology firm's main asset against over-active bladder disorder (OAB) in a big clinical trial in the US. The company is expecting to release the results as soon as next year, and hopes for a potential launch in 2024-2025.

Photo: Coloplast / PR

Coloplast is taking its first step into a new segment of the urology area. The medtech company has just made the final preparations for an extensive clinical study with the company's solution, a "tibial nerve stimulator," for over-active bladder disorder (OAB), the company reports in a press release.

"We will begin in the current quarter and expect the first results sometime during next year," President and CFO Anders Lonning-Skovgaard tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs